μetaRadiology provides disease-oriented maps for deeper insights on monitoring conditions such as Multiple Sclerosis, liver steatosis/hemosiderosis, and osteoporosis into the workflow.
CAPABILITIES
Disease-specific quantification and reporting
Liver Steatosis
Liver fat content is quantified precisely and non-invasively, allowing fatty liver disease to be staged and characterised even in asymptomatic patients. The resulting measurements support clinical decision-making and provide a consistent basis for longitudinal patient monitoring.
Osteoporosis
Bone density is assessed accurately without the need for a separate DEXA examination, giving an objective basis for fracture risk assessment and preventive strategies. Consistent follow-up comparison supports therapy evaluation and tracking of progression over time.
Hemosiderosis
Liver iron concentration is quantified to support accurate diagnosis and comparison against prior studies, reducing reliance on liver biopsy. Non-invasive assessment can be repeated as required, allowing treatment response to be monitored reliably throughout the course of care.
Multiple Sclerosis
Lesions are segmented and quantified across multiple time points, enabling automated monitoring of disease progression and clearer clinical insight. Objective, repeatable measurements support standardised reporting and consistent comparison in MS follow-up.
the μetaradiology value
Quantitative measurement, built into routine imaging.
Metaradiology applies quantitative biomarker mapping to standard MRI studies, turning routine acquisitions into structured, disease-oriented measurements.
Quantitative MRI biomarker mapping
Disease-oriented reporting
Single, modular intelligence layer
Research-grade outputs
Optimized protocols & algorithms
Clinically enhanced timeframes
From asymtomatic to finding
Precise, non-invasive quantification of liver fat fraction allows fatty liver disease to be staged and characterised from existing imaging. The resulting measurements give clinicians a consistent basis for decision-making and longitudinal monitoring.
- No biopsy. No additional acquisition. No manual measurement.
- Quantified, staged and comparable across every follow-up study.
- Available within the existing reading workflow.
-
Scan acquisition
-
Liver ROI is outlined
-
Fat Fraction quantification
-
Report is generated
